Review Proposes NAD+-Sirtuin-Mitochondrial Quality Control Network as Modulator of Crystalline Lens Aging

A newly proposed conceptual framework links NAD+ homeostasis and mitochondrial quality control in lens epithelial cells to crystalline lens aging, outlining three experimental levels to validate therapeutic targets for presbyopia and cataracts.

Researchers published a synthesis of current lens and lens epithelial cell (LEC) evidence in Experimental Eye Research, proposing that the NAD(+)-sirtuin-mitochondrial quality control (MQC) network in LECs modulates crystalline lens aging.

The review highlights existing data showing age-associated declines in mitochondrial oxygen consumption in human LECs, the role of SIRT1-related signaling in stress tolerance, and the protective effects of PINK1/Parkin-dependent mitophagy and autophagy-lysosomal function in stress models.

To substantiate this candidate modulator network, the authors propose three falsifiable levels of validation: age-stratified measurement of NAD+ homeostasis in human LECs, testing whether NAD+ restoration improves sirtuin-dependent MQC, and determining whether verifying LEC MQC rescue preserves overall lens homeostasis and transparency.

Cataracts and presbyopia represent highly prevalent age-related conditions that currently lack disease-modifying pharmacological therapies, relying instead on surgical or corrective options.

If validated, this framework establishes a clear link between systemic aging pathways (such as NAD+ decline and mitochondrial dysfunction) and localized organ deterioration in the eye.

The focus on lens epithelial cells shifts therapeutic attention toward maintaining the active metabolic and cellular protective machinery of the lens to prevent downstream structural crystallin damage.

The identification of mitochondrial quality control and autophagy as key components in preserving lens function could eventually expand the clinical indications of companies working on mitophagy-inducing and autophagy-restoring platforms.

Confirmation of an epithelial-to-tissue causal pathway may drive preclinical interest and ophthalmic drug-delivery research focused on localized sirtuin activators or NAD+ precursors.

Age-stratified studies analyzing NAD+ homeostasis in human LECs to confirm if normal tissue aging matches the proposed metabolic decline.

Preclinical testing of NAD+ restoration therapies or mitophagy-inducing agents to determine if they successfully rescue mitochondrial quality control and mitigate crystallin damage in intact-lens models.